These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35580650)

  • 21. Novel therapeutic targets and predictive markers for hepatocellular carcinoma.
    Chan SL; Chan AW; Yeo W
    Expert Opin Ther Targets; 2015 Jul; 19(7):973-83. PubMed ID: 25910512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials.
    Noonan A; Pawlik TM
    Expert Opin Investig Drugs; 2019 Nov; 28(11):941-949. PubMed ID: 31590579
    [No Abstract]   [Full Text] [Related]  

  • 23. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
    World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
    Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy for hepatocellular carcinoma: current status and future perspectives.
    Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications.
    Frenette C; Gish R
    World J Gastroenterol; 2012 Feb; 18(6):498-506. PubMed ID: 22363115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review article: systemic treatment of hepatocellular carcinoma.
    Pinter M; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
    Su GL; Altayar O; O'Shea R; Shah R; Estfan B; Wenzell C; Sultan S; Falck-Ytter Y
    Gastroenterology; 2022 Mar; 162(3):920-934. PubMed ID: 35210014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paradigm shift in the treatment options of hepatocellular carcinoma.
    Su TH; Hsu SJ; Kao JH
    Liver Int; 2022 Aug; 42(9):2067-2079. PubMed ID: 34515412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An update on atezolizumab for hepatocellular carcinoma.
    Ielasi L; Sansone V; Forgione A; Granito A; Benevento F; Tovoli F
    Drugs Today (Barc); 2021 Jun; 57(6):365-375. PubMed ID: 34151903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma.
    Rimassa L; Wörns MA
    Liver Int; 2020 Aug; 40(8):1800-1811. PubMed ID: 32432830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future.
    Patel A; Sun W
    Curr Treat Options Oncol; 2014 Sep; 15(3):380-94. PubMed ID: 24838298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New systemic agents for hepatocellular carcinoma: an update 2020.
    von Felden J
    Curr Opin Gastroenterol; 2020 May; 36(3):177-183. PubMed ID: 32101985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
    Kim DY
    Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
    Sun W; Cabrera R
    J Gastrointest Cancer; 2018 Jun; 49(2):107-115. PubMed ID: 29453759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatocellular carcinoma, novel therapies on the horizon.
    El Dika I; Makki I; Abou-Alfa GK
    Chin Clin Oncol; 2021 Feb; 10(1):12. PubMed ID: 32527116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic therapies in hepatocellular carcinoma.
    Wörns MA; Weinmann A; Schuchmann M; Galle PR
    Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA; Galle PR
    Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.